menu search

: voyager, neurocrine ink gene-therapy deal

Shares of Voyager Therapeutics Inc. VYGR rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc...

January 9, 2023, 1:15 pm

Voyager, neurocrine ink gene-therapy deal

Shares of Voyager Therapeutics Inc. VYGR, +10.65% rallied 35% in premarket trading on Monday after the company announced a deal with Neurocrine Biosci...

January 9, 2023, 8:15 am

Astrazeneca will buy u.s.-based cincor for cardiorenal asset

AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter's baxdrostat cardiorenal drug for an ...

January 9, 2023, 2:29 am

Cymabay therapeutics announces collaboration with kaken pharmaceutical co., ltd. to develop and commercialize seladelpar in japan for primary biliary cholangitis

Advances strategy to partner seladelpar for PBC outside U.S. Brings in approximately $34.0 million upfront...

January 8, 2023, 5:00 pm

Warner bros. discovery signs audience measurement deal with startup nielsen rival videoamp

Warner Bros. Discovery has agreed to use measurement platform VideoAmp ahead of the 2023 upfronts....

January 3, 2023, 9:00 am

Incentives could shave 70% off price of nikola fuel cell truck

If Nikola qualifies for California's $240,000 subsidy on its Tre hydrogen fuel cell electric truck and some other spiffs apply, a buyer could save 40%...

December 27, 2022, 3:20 pm

Lilly, sosei to develop new treatments for diabetes and metabolic diseases

Eli Lilly & Co. Inc. and Sosei Group Corp. said Friday they plan to develop and commercialize therapies for diabetes and metabolic diseases. Lilly is ...

December 16, 2022, 7:50 am

Lyft drivers to receive discounted charging with evgo

One of the core advantages of owning an electric vehicle over a gas-powered one is that, despite the higher up...

December 13, 2022, 12:53 pm

Gilead to co-develop arcellx's multiple myeloma drug

Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment cand...

December 9, 2022, 8:46 am

Biopharma co.’s shares triple in value on us$5b license deal

Source: Streetwise Reports (12/7/22) Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-lic...

December 8, 2022, 1:30 pm

New research partnership with horizon therapeutics could be the next revenue catalyst for xeris

Technology-based biopharma company Xeris (US:XERS) is set to boost its revenue with an upfront cash pay...

November 28, 2022, 8:01 pm

Surgepays keeps growing

Revenues up 149%, following subscriber growth but the bottom line isn't yet improving as a result of upfront...

November 17, 2022, 2:23 pm

Roku: cathie wood is still right

Roku quickly bounced back after a crushing guide down for Q4. The company continues to be hit by weakness in the ad scatter market while the key video...

November 14, 2022, 9:28 am

Palantir: a software company playing 4d chess, while critics and competition are still learning to play checkers

Palantir's business model is built on proving quantifiable returns and value back to the customer with its software, and they are willing to lose mone...

November 13, 2022, 11:14 am

Poseida therapeutics: collaboration agreement with roche helps validate genetic engineering tech

Poseida announced a collaboration agreement on Aug.3 focused on allogeneic CAR-T Program in hematologic cancers with Roche, potentially worth $6 billi...

September 4, 2022, 3:30 am

Maverix metals acquires portfolio of 22 royalties from barrick gold corp

Maverix Metals Inc (TSX:MMX) said it has acquired a portfolio of 22 royalties from Barrick Gold Corp for an up...

September 2, 2022, 7:22 am

Splunk remains an acquisition target

Splunk continues to chalk up fundamental progress as it moves from perpetual upfront billing towards a ...

August 23, 2022, 9:28 am

Poseida therapeutics: even after recent partnership, additional upside possible

Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data readouts from both of these candidates a...

August 3, 2022, 3:09 pm

Sesen (sesn) halts bladder cancer drug development, stock down

Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange ...

July 19, 2022, 1:55 pm

Disney sets company record with $9b in upfront ad commitments, nearly half of them on streaming and digital

Disney has wrapped its upfront advertising sales process, collecting a record $9 billion — 40% of it ...

July 18, 2022, 5:03 pm


Search within

Pages Search Results: